References
1. Filigheddu MT, Górgolas M, Ramos JM. Enfermedad de Chagas de
transmisión oral. Med Clin (Barc) . 2017;148(3):125-131.
doi:10.1016/j.medcli.2016.10.038
2. WHO | Epidemiology. WHO.
3. Coura JR, Viñas PA, Junqueira ACV. Ecoepidemiology, Short history and
control of chagas disease in the endemic countries and the new challenge
for non-endemic countries. Mem Inst Oswaldo Cruz .
2014;109(7):856-862. doi:10.1590/0074-0276140236
4. Martins-Melo FR, da Silveira Lima M, Ramos AN, Alencar CH, Heukelbach
J. Systematic review: Prevalence of Chagas disease in pregnant women and
congenital transmission of Trypanosoma cruzi in Brazil: A systematic
review and meta-analysis. Trop Med Int Heal . 2014;19(8):943-957.
doi:10.1111/tmi.12328
5. Basile L, Ciruela P, Requena-Méndez A, et al. Epidemiology of
congenital Chagas disease 6 years after implementation of a public
health surveillance system, Catalonia, 2010 to 2015.Eurosurveillance . 2019;24(26).
doi:10.2807/1560-7917.ES.2019.24.26.19-00011
6. Coura JR, de Abreu LL, Pereira JB, Willcox HP. Morbidade da doenĉa de
Chagas. IV. Estudo longitudinal de dez anos emPains e Iguatama, Minas
Gerais, Brasil. Mem Inst Oswaldo Cruz . 1985;80(1):73-80.
doi:10.1590/s0074-02761985000100011
7. Pérez-Molina JA, Molina I. Chagas disease. Lancet .
2018;391(10115):82-94. doi:10.1016/S0140-6736(17)31612-4
8. Altcheh J, Moscatelli G, Mastrantonio G, et al. Population
Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease
Suggests Efficacy despite Lower Plasma Concentrations than in Adults.PLoS Negl Trop Dis . 2014;8(5). doi:10.1371/journal.pntd.0002907
9. Moscatelli G, Moroni S, García-Bournissen F, et al. Prevention of
congenital chagas through treatment of girls and women of childbearing
age. Mem Inst Oswaldo Cruz . 2015;110(4):507-509.
doi:10.1590/0074-02760140347
10. Sosa-Estani S, Colantonio L, Segura EL. Therapy of chagas disease:
implications for levels of prevention. J Trop Med .
2012;2012:292138. doi:10.1155/2012/292138
11. Paho, Who. Guidelines for the diagnosis and treatment of Chagas
disease. 2019. www.paho.org/permissions. Accessed May 29, 2020.
12. Laucella SA, Mazliah DP, Bertocchi G, et al. Changes in Trypanosoma
cruzi –Specific Immune Responses after Treatment: Surrogate Markers of
Treatment Efficacy . Clin Infect Dis . 2009;49(11):1675-1684.
doi:10.1086/648072
13. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of
benznidazole for chronic chagas’ cardiomyopathy. N Engl J Med .
2015;373(14):1295-1306. doi:10.1056/NEJMoa1507574
14. Issa VS, Bocchi EA. Antitrypanosomal agents: Treatment or threat?Lancet . 2010;376(9743):768. doi:10.1016/S0140-6736(10)61372-4
15. Bern C, Martin DL, Gilman RH. Acute and Congenital Chagas Disease.
In: Advances in Parasitology . Vol 75. Academic Press; 2011:19-47.
doi:10.1016/B978-0-12-385863-4.00002-2
16. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of
treating chronic chagas disease with benznidazole versus no treatment: A
nonrandomized trial. Ann Intern Med . 2006;144(10):724-734.
doi:10.7326/0003-4819-144-10-200605160-00006
17. Echeverría LE, Rojas LZ, Rueda‐Ochoa OL, et al. Circulating
Trypanosoma Cruzi Load and Major Cardiovascular Outcomes in Patients
with Chronic Chagas Cardiomyopathy: A Prospective Cohort Study.Trop Med Int Heal . 2020;(Accepted Author Manuscript).
doi:10.1111/TMI.13487
18. Rassi A, Marin-Neto JA, Rassi A. Chronic chagas cardiomyopathy: A
review of the main pathogenic mechanisms and the efficacy of
aetiological treatment following the BENznidazole evaluation for
interrupting trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo
Cruz . 2017;112(3):224-235. doi:10.1590/0074-02760160334
19. Müller Kratz J, Garcia Bournissen F, Forsyth CJ, Sosa-Estani S.
Clinical and pharmacological profile of benznidazole for treatment of
Chagas disease. Expert Rev Clin Pharmacol . 2018;11(10):943-957.
doi:10.1080/17512433.2018.1509704
20. London Declaration on Neglected Tropical Diseases.
https://www.who.int/neglected_diseases/London_Declaration_NTDs.pdf.
Accessed September 11, 2020.
21. Bartsch SM, Avelis CM, Asti L, et al. The economic value of
identifying and treating Chagas disease patients earlier and the impact
on Trypanosoma cruzi transmission. Angheben A, ed. PLoS Negl Trop
Dis . 2018;12(11):1-24. doi:10.1371/journal.pntd.0006809
22. Altcheh J. La enfermedad de Chagas a 100 años de su descubrimiento.Arch Argent Pediatr . 2010;108(1):4-5.
23. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected
tropical diseases. Lancet . 2010;375(9710):239-247.
doi:10.1016/S0140-6736(09)61422-7
24. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of
Chagas disease: A computational simulation model. Lancet Infect
Dis . 2013;13(4):342-348. doi:10.1016/S1473-3099(13)70002-1
25. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o
ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente
etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo
Cruz . 1909;1(2):159-218. doi:10.1590/s0074-02761909000200008
26. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal
type I nitroreductases generates cytotoxic nitrile metabolites. J
Biol Chem . 2011;286(15):13088-13095. doi:10.1074/jbc.M111.230847
27. Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal
type I nitroreductases results in glyoxal formation. Antimicrob
Agents Chemother . 2012;56(1):115-123. doi:10.1128/AAC.05135-11
28. Vázquez K, Paulino M, Salas CO, Zarate-Ramos JJ, Vera B, Rivera G.
Trypanothione Reductase: A Target for the Development of Anti-
Trypanosoma cruzi Drugs. Mini-Reviews Med Chem .
2017;17(11):939-946. doi:10.2174/1389557517666170315145410
29. García-Bournissen F, Moroni S, Marson ME, et al. Limited infant
exposure to benznidazole through breast milk during maternal treatment
for Chagas disease. Arch Dis Child . 2015;100(1):90-94.
doi:10.1136/archdischild-2014-306358
30. Moroni S, Marson ME, Moscatelli G, et al. Negligible exposure to
nifurtimox through breast milk during maternal treatment for Chagas
Disease. PLoS Negl Trop Dis . 2019;13(8):1-10.
doi:10.1371/journal.pntd.0007647
31. Garcia-Bournissen F, Altcheh J, Panchaud A, Ito S. Is use of
nifurtimox for the treatment of Chagas disease compatible with breast
feeding? A population pharmacokinetics analysis. Arch Dis Child .
2010;95(3):224-228. doi:10.1136/adc.2008.157297
32. Vasquez I, Paredes J, Gonzalez Martin G, Thambo S PC. The
pharmacokinetics of nifurtimox in chronic renal failure. Eur J
Clin Pharmacol . 1992;42(6):671–3. doi:10.1007/BF00265935
33. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA, Mirtha
Streiger Paraje El Pozo DL. Estudo longitudinal e quimioterapia
específica em crianças, com doença de Chagas crônica, residentes em área
de baixa endemicidade da República Argentina Longitudinal study and
specific chemotherapy in children with chronic Chagas’ disease, residing
in a. Rev Soc Bras Med Trop . 2004;37(5):365-375.
doi:https://doi.org/10.1590/S0037-86822004000500001
34. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H.
Adverse events after the use of benznidazole in infants and children
with Chagas disease. Pediatrics . 2011;127(1):e212-e218.
doi:10.1542/peds.2010-1172
35. Sgambatti De Andrade ALS, Zicker F, De Oliveira RM, et al.
Randomised trial of efficacy of benznidazole in treatment of early
Trypanosoma cruzi infection. Lancet . 1996;348(9039):1407-1413.
doi:10.1016/S0140-6736(96)04128-1
36. Coura JR, De Castro SL. A critical review on chagas disease
chemotherapy. Mem Inst Oswaldo Cruz . 2002;97(1):3-24.
doi:10.1590/S0074-02762002000100001
37. Lauria-Pires L, Braga MS, Vexenat AC, et al. Progressive chronic
chagas heart disease ten years after treatment with anti-Trypanosoma
cruzi nitroderivatives. Am J Trop Med Hyg . 2000;63(3-4):111-118.
doi:10.4269/ajtmh.2000.63.111
38. Fernández ML, Marson ME, Ramirez JC, et al. Pharmacokinetic and
pharmacodynamic responses in adult patients with chagas disease treated
with a new formulation of benznidazole. Mem Inst Oswaldo Cruz .
2016;111(3):218-221. doi:10.1590/0074-02760150401
39. Villar JC, Herrera VM, Pérez Carreño JG, et al. Nifurtimox versus
benznidazole or placebo for asymptomatic Trypanosoma cruzi infection
(Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): Study
protocol for a randomised controlled trial. Trials . 2019;20(1).
doi:10.1186/s13063-019-3423-3
40. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis
C. Efficacy of chemotherapy with benznidazole in children in the
indeterminate phase of Chagas’ disease. Am J Trop Med Hyg .
1998;59(4):526-529. doi:10.4269/ajtmh.1998.59.526
41. Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of
congenital Chagas’ disease diagnosed and monitored by the polymerase
chain reaction. J Antimicrob Chemother . 2003;52(3):441-449.
doi:10.1093/jac/dkg338
42. Chippaux JP, Clavijo ANS, Santalla JA, Postigo JR, Schneider D,
Brutus L. Antibody drop in newborns congenitally infected by Trypanosoma
cruzi treated with benznidazole. Trop Med Int Heal .
2010;15(1):87-93. doi:10.1111/j.1365-3156.2009.02431.x
43. Marson ME, Altcheh J, Moscatelli G, Moroni S, García-Bournissen F,
Mastrantonio GE. Identification of N-Benzylacetamide as a Major
Component of Human Plasmatic Metabolic Profiling of Benznidazole . Vol
40. Springer-Verlag France; 2015:209-217. doi:10.1007/s13318-014-0195-8
44. Vallejo A, Monge-Maillo B, Gutiérrez C, Norman FF, López-Vélez R,
Pérez-Molina JA. Changes in the immune response after treatment with
benznidazole versus no treatment in patients with chronic indeterminate
Chagas disease. Acta Trop . 2016;164:117-124.
doi:10.1016/j.actatropica.2016.09.010
45. Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for
chronic asymptomatic Trypanosoma cruzi infection. Cochrane
Database Syst Rev . 2014;2014(5). doi:10.1002/14651858.CD003463.pub2
46. Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for
evaluating therapeutic efficacy in Chagas disease, a systematic review.Expert Rev Anti Infect Ther . 2014;12(4):479-496.
doi:10.1586/14787210.2014.899150
47. Albareda MC, Natale MA, De Rissio AM, et al. Distinct treatment
outcomes of antiparasitic therapy in trypanosoma cruzi-infected children
is associated with early changes in Cytokines, Chemokines, and T-Cell
Phenotypes. Front Immunol . 2018;9:1-15.
doi:10.3389/fimmu.2018.01958
48. Olivera MJ, Fory JA, Olivera AJ. Therapeutic drug monitoring of
benznidazole and nifurtimox: A systematic review and quality assessment
of published clinical practice guidelines. Rev Soc Bras Med Trop .
2017;50(6):748-755. doi:10.1590/0037-8682-0399-2016
49. Jannin J, Villa L. An overview of Chagas disease treatment. In:Memorias Do Instituto Oswaldo Cruz . Vol 102. ; 2007:95-97.
doi:10.1590/s0074-02762007005000106
50. Pinheiro E, Brum-Soares L, Reis R, Cubides JC. Chagas disease:
Review of needs, neglect, and obstacles to treatment access in Latin
America. Rev Soc Bras Med Trop . 2017;50(3):296-300.
doi:10.1590/0037-8682-0433-2016
51. Alpern JD, Lopez-Velez R, Stauffer WM. Access to benznidazole for
Chagas disease in the United States—Cautious optimism? PLoS Negl
Trop Dis . 2017;11(9):e0005794. doi:10.1371/journal.pntd.0005794
52. Francisco AF, Jayawardhana S, Lewis MD, et al. Nitroheterocyclic
drugs cure experimental Trypanosoma cruzi infections more effectively in
the chronic stage than in the acute stage. Sci Rep .
2016;6(1):35351. doi:10.1038/srep35351
53. Chatelain E. Chagas disease drug discovery: Toward a new era.J Biomol Screen . 2015;20(1):22-35. doi:10.1177/1087057114550585
54. Richle RW, Raaflaub J. Difference of effective antitrypanosomal
dosages of benznidazole in mice and man. Chemotherapeutic and
pharmacokinetic results. Acta Trop . 1980;37(3):257-261.
http://www.ncbi.nlm.nih.gov/pubmed/6106364.
55. Romanha AJ, de Castro SL, Soeiro M de NC, et al. In vitro and in
vivo experimental models for drug screening and development for Chagas
disease. Mem Inst Oswaldo Cruz . 2010;105(2):233-238.
doi:10.1590/S0074-02762010000200022
56. Chatelain E, Ioset JR. Phenotypic screening approaches for Chagas
disease drug discovery. Expert Opin Drug Discov .
2018;13(2):141-153. doi:10.1080/17460441.2018.1417380
57. The Biopharmaceutics Classification System (BCS) Guidance |
FDA.
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/biopharmaceutics-classification-system-bcs-guidance.
Accessed September 10, 2020.
58. del Moral Sanchez JM, Gonzalez-Alvarez I, Cerda-Revert A, et al.
Biopharmaceutical optimization in neglected diseases for paediatric
patients by applying the provisional paediatric biopharmaceutical
classification system. Br J Clin Pharmacol .
2018;84(10):2231-2241. doi:10.1111/bcp.13650
59. Trochine A, Creek DJ, Faral-Tello P, Barrett MP, Robello C.
Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi
Revealed by Metabolomics. Pollastri MP, ed. PLoS Negl Trop Dis .
2014;8(5):e2844. doi:10.1371/journal.pntd.0002844
60. Zingales B, Araujo RGA, Moreno M, et al. A novel ABCG-like
transporter of Trypanosoma cruzi is involved in natural resistance to
benznidazole. Mem Inst Oswaldo Cruz . 2015;110(3):433-444.
doi:10.1590/0074-02760140407
61. Moreno M, D’ávila DA, Silva MN, et al. Trypanosoma cruzi
benznidazole susceptibility in vitro does not predict the therapeutic
outcome of human Chagas disease. Mem Inst Oswaldo Cruz .
2010;105(7):918-924. doi:10.1590/S0074-02762010000700014
62. Canavaci AMC, Bustamante JM, Padilla AM, et al. In Vitro and In Vivo
High-throughput assays for the testing of Anti-trypanosoma cruzi
compounds. Geary TG, ed. PLoS Negl Trop Dis . 2010;4(7):e740.
doi:10.1371/journal.pntd.0000740
63. Moraes CB, Giardini MA, Kim H, et al. Nitroheterocyclic compounds
are more efficacious than CYP51 inhibitors against Trypanosoma cruzi:
Implications for Chagas disease drug discovery and development.Sci Rep . 2014;4(1):1-11. doi:10.1038/srep04703
64. Polak A, Richle R. Mode of action of the 2-nitroimidazole derivative
benznidazole. Ann Trop Med Parasitol . 1978;72(1):45-54.
doi:10.1080/00034983.1978.11719278
65. Molina I, Salvador F, Sánchez-Montalvá A, et al. Pharmacokinetics of
benznidazole in healthy volunteers and implications in future clinical
trials. Antimicrob Agents Chemother . 2017;61(4):139-144.
doi:10.1128/AAC.01912-16
66. Raaflaub J. Multiple-dose kinetics of the trypanosomicide
benznidazole in man. Arzneimittelforschung .
1980;30(12):2192-2194. http://www.ncbi.nlm.nih.gov/pubmed/6783051.
67. Roberts JT, Bleehen NM. Benznidazole with CCNU: A clinical phase i
toxicity study. Int J Radiat Oncol Biol Phys . 1985;11(2):331-334.
doi:10.1016/0360-3016(85)90155-5
68. Workman P, White RA, Walton MI, Owen LN, Twentyman PR. Preclinical
pharmacokinetics of benznidazole. Br J Cancer .
1984;50(3):291-303. doi:10.1038/bjc.1984.176
69. Bisio M, Altcheh J, Lattner J, et al. Benznidazole treatment of
chagasic encephalitis in pregnant woman with AIDS. Emerg Infect
Dis . 2013;19(9):1490-1492. doi:10.3201/eid1909.130667
70. Cordova E, Boschi A, Ambrosioni J, Cudos C, Corti M. Reactivation of
Chagas disease with central nervous system involvement in HIV-infected
patients in Argentina, 1992-2007. Int J Infect Dis .
2008;12(6):587-592. doi:10.1016/j.ijid.2007.12.007
71. Cohen V, Ceballos V, Rodríguez N, et al. Chagas’ disease as a cause
of cerebral mass in a patient with lymphoblastic leukemia in remission.Arch Argent Pediatr . 2010;108(6).
doi:10.1590/S0325-00752010000600016
72. Montero M, Mir M, Sulleiro E, et al. High-dose benznidazole in a
62-year-old Bolivian kidney transplant recipient with Chagas central
nervous system involvement. Int J Infect Dis . 2019;78:103-106.
doi:10.1016/j.ijid.2018.10.014
73. Walton MI, Workman P. Nitroimidazole bioreductive metabolism.
Quantitation and characterisation of mouse tissue benznidazole
nitroreductases in vivo and in vitro. Biochem Pharmacol .
1987;36(6):887-896. doi:10.1016/0006-2952(87)90181-X
74. Rocco D, Perez Montilla C, Moroni S, Altcheh J G-BF. F Benznidazole
metabolites in urine from patients treated for Chagas disease Abstract.Meet Am Soc Clin Pharmacol . 2018.
75. Ministerio de Salud y Desarrollo Social de la Republica Argentina.Atención Del Paciente Infectado Con Trypanosoma Cruzi, Guia Para
El Equipo de Salud, 3° Edición-2018 .
76. Viotti R, Alarcón De Noya B, Araujo-Jorge T, et al. Towards a
paradigm shift in the treatment of chronic chagas disease.Antimicrob Agents Chemother . 2014;58(2):635-639.
doi:10.1128/AAC.01662-13
77. Álvarez MG, Hernández Y, Bertocchi G, et al. New scheme of
intermittent benznidazole administration in patients chronically
infected with Trypanosoma cruzi: A pilot short-term follow-up study with
adult patients. Antimicrob Agents Chemother . 2016;60(2):833-837.
doi:10.1128/AAC.00745-15
78. Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of
benznidazole in adult patients with Chagas disease. Antimicrob
Agents Chemother . 2015;59(6):3342-3349. doi:10.1128/AAC.05018-14
79. Cafferata ML, Toscani MA, Althabe F, et al. Short-course
Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in
women of reproductive age (BETTY): a non-inferiority randomized
controlled trial study protocol. Reprod Health . 2020;17(1):128.
doi:10.1186/s12978-020-00972-1
80. Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J.
Benznidazole-related adverse drug reactions and their relationship to
serum drug concentrations in patients with chronic chagas disease.Antimicrob Agents Chemother . 2013;57(1):390-395.
doi:10.1128/AAC.01401-12
81. Aldasoro E, Posada E, Requena-Méndez A, et al. What to expect and
when: Benznidazole toxicity in chronic Chagas’ disease treatment.J Antimicrob Chemother . 2018;73(4):1060-1067.
doi:10.1093/jac/dkx516
82. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole
as treatment in chronic Chagas disease: Fears and realities.Expert Rev Anti Infect Ther . 2009;7(2):157-163.
doi:10.1586/14787210.7.2.157
83. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and
effectiveness of etiological treatment programs for Chagas disease in
Honduras, Guatemala, and Bolivia: 10-Year experience of Médecins Sans
Frontières. Gürtler RE, ed. PLoS Negl Trop Dis . 2009;3(7):e488.
doi:10.1371/journal.pntd.0000488
84. Sperandio da Silva GM, Mediano MFF, Hasslocher-Moreno AM, et al.
Benznidazole treatment safety: the Médecins Sans Frontières experience
in a large cohort of Bolivian patients with Chagas’ disease. J
Antimicrob Chemother . 2017;72(9):2596-2601. doi:10.1093/jac/dkx180
85. Bertocchi GL, Vigliano CA, Lococo BG, Petti MA, Viotti RJ. Clinical
characteristics and outcome of 107 adult patients with chronic Chagas
disease and parasitological cure criteria. Trans R Soc Trop Med
Hyg . 2013;107(6):372-376. doi:10.1093/TRSTMH/TRT029
86. de Pontes V, de Souza Júnior A, da Cruz F, Coelho H, Dias A, Coêlho
I, de Fátima O. Adverse reactions in Chagas disease patients treated
with benznidazole, in the State of Ceara. Rev Soc Bras Med Trop .
2010;43(2):182-187. doi:S0037-86822010000200015
87. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Araujo G, Lococo B,
Ruiz Vera B, Vigliano C, de Rissio AM S EL. Treatment of Chagas Disease
With Benznidazole and Thioctic Acid. Medicina (B Aires) .
2004;64(1).
88. Bartel LC, Montalto De Mecca M, Rodríguez De Castro C, Bietto FM,
Castro JA. Metabolization of nifurtimox and benznidazole in cellular
fractions of rat mammary tissue. Hum Exp Toxicol .
2010;29(10):813-822. doi:10.1177/0960327110361756
89. Docampo R, Moreno SNJ, Stoppani AOM. Nitrofuran enhancement of
microsomal electron transport, superoxide anion production and lipid
peroxidation. Arch Biochem Biophys . 1981;207(2):316-324.
doi:10.1016/0003-9861(81)90039-4
90. Arancibia A, Gonzalez Martin G, Paulos C, Paredes J,Vasquez I
,Thambo S. Pharmacokinetics of a nitrofuran compound, nifurtimox, in
healthy volunteers. Int J Clin Pharmacol Ther Toxicol .
1989;27(9):454-457.
91. Patzschke K, Wegner LA, Duhm B, Maul W MH. Investigations on the
pharmacokinetics of nifurtimox- 35 S in the rat and dog.Arzneimittelforschung . 1972;22(9):1617-1624.
https://www.ncbi.nlm.nih.gov/pubmed/4630484.
92. Kuemmerle A, Schmid C, Kande V, et al. Prescription of concomitant
medications in patients treated with Nifurtimox Eflornithine Combination
Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the
Democratic Republic of the Congo. PLoS Negl Trop Dis .
2020;14(1):e0008028. doi:10.1371/journal.pntd.0008028
93. Paulos, C. Paredes, J. Vasquez I, Kunze, G. González-Martin G.
High-performance liquid chromatographic determination of nifurtimox in
human serum. J Chromatogr B Biomed Sci Appl . 1988;433(C):359-362.
doi:10.1016/S0378-4347(00)80621-0
94. Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study
of nifurtimox in patients with relapsed/refractory neuroblastoma.J Pediatr Hematol Oncol . 2011;33(1):25-30.
doi:10.1097/MPH.0b013e3181f47061
95. Raether W, Hänel H. Nitroheterocyclic drugs with broad spectrum
activity. Parasitol Res . 2003;90(S1):S19-S39.
doi:10.1007/s00436-002-0754-9
96. Heino Strass, Ethel Feleder, Facundo Garcia-Bournisen, Johannes
Nagelschmitz, Boris Weimann, Gustavo Yerino JA. Biopharmaceutical
characteristics of nifurtimox tablets for age and bodyweight adjusted
dosing in patients with Chagas disease. Clin Pharmacol Drug Dev .
2020. doi:10.1002/cpdd.871
97. Gonzalez-Martin G, Paulos C, Guevara A PG. Disposition of nifurtimox
and metabolite activity against Trypanosoma cruzi using rat isolated
perfused liver. J Pharm Pharmacol . 1994;46(5):356-359.
doi:10.1111/j.2042-7158.1994.tb03812.x
98. Pérez Montilla C, Moroni S, González N, Moscatelli G, Altcheh J,
García Bournissen F. P38 Identification of Nifurtimox metabolites in
urine of pediatric Chagas disease patients by UHPLC-MS/MS. Arch
Dis Child . 2019;104(6):e32.3-e33.
doi:10.1136/archdischild-2019-esdppp.76
99. Letelier ME, Izquierdo P, Godoy L, Lepe AM, Faúndez M. Liver
microsomal biotransformation of nitro-aryl drugs: Mechanism for
potential oxidative stress induction. J Appl Toxicol .
2004;24(6):519-525. doi:10.1002/jat.999
100. Masana M, de Toranzo EG CJ. Studies on nifurtimox nitroreductase
activity in liver and other rat tissues. Arch Int Pharmacodyn
Ther . 1984:270. https://www.ncbi.nlm.nih.gov/pubmed/6497502.
101. Watson CP, Dogruel M, Mihoreanu L, et al. The transport of
nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human
blood-brain barrier: Evidence for involvement of breast cancer
resistance protein. Brain Res . 2012;1436:111-121.
doi:10.1016/j.brainres.2011.11.053
102. Cancado J, Salgado A, Marra D, Alvares J MJ. [Clinical
therapeutic trial in chronic Chagas’ disease using nifurtimox in 3
schedules of long duration]. Ensaio terapeutico cl’inico na doenca de
Chagas cronica com o nifurtimox em tres esquemas de dura coa prolongada.
Rev Inst Med Trop Sao Paulo. Rev Inst Med Trop Sao Paulo .
1975;17(2):111-127.
103. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F.
Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas
Disease. Clin Infect Dis . 2010;51(10):e69-e75. doi:10.1086/656917
104. Ribeiro V, Dias N, Paiva T, et al. Current trends in the
pharmacological management of Chagas disease. Int J Parasitol
Drugs Drug Resist . 2020;12:7-17. doi:10.1016/j.ijpddr.2019.11.004
105. Forsyth CJ, Hernandez S, Olmedo W, Abuhamidah A, Traina MI SD.
Safety Profile of Nifurtimox for Treatment of Chagas Disease in the
United States. Clin Infect Dis . 2016;63(8):1056-1062.
doi:10.1093/cid/ciw477
106. Alarcón de Noya B, Ruiz-Guevara R, Noya O, et al. Long-term
comparative pharmacovigilance of orally transmitted Chagas disease:
first report. Expert Rev Anti Infect Ther . 2017;15(3):319-325.
doi:10.1080/14787210.2017.1286979
107. Freilij, H., Altcheh J. Congenital Chagas’ Disease: Diagnostic and
Clinical Aspects. Clin Infect Dis . 1995;21(3).
doi:10.1093/CLINIDS/21.3.551
108. Pérez-Molina JA, Sojo-Dorado J, Norman F, et al. Nifurtimox therapy
for Chagas disease does not cause hypersensitivity reactions in patients
with such previous adverse reactions during benznidazole treatment.Acta Trop . 2013;127(2):101-104.
doi:10.1016/j.actatropica.2013.04.003
109. Moscatelli G, Moroni S, Bournissen FG, et al. Longitudinal follow
up of serological response in children treated for Chagas disease.
Angheben A, ed. PLoS Negl Trop Dis . 2019;13(8):1-14.
doi:10.1371/journal.pntd.0007668
110. Alonso-Vega C, Billot C, Torrico F. Achievements and Challenges
upon the Implementation of a Program for National Control of Congenital
Chagas in Bolivia: Results 2004-2009. PLoS Negl Trop Dis .
2013;7(7). doi:10.1371/journal.pntd.0002304
111. Garcia-Bournissen F, Altcheh J, Giglio N, Mastrantonio G, Omar
Della Védova C, Koren G. Pediatric clinical pharmacology studies in
Chagas disease: Focus on Argentina. In: Pediatric Drugs . Vol 11.
; 2009:33-37. doi:10.2165/0148581-200911010-00012
112. Cançado JR. Long term evaluation of etiological treatment of Chagas
disease with benznidazole. Rev Inst Med Trop Sao Paulo .
2002;44(1):29-37. doi:10.1590/S0036-46652002000100006
113. Andrade ALSS, Martelli CMT, Oliveira RM, et al. Short report:
Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after
a six-year follow-up. Am J Trop Med Hyg . 2004;71(5):594-597.
doi:10.4269/ajtmh.2004.71.594
114. Fabbro DL, Streiger ML, Arias ED, Bizai ML, Del Barco M, Amicone
NA. Trypanocide treatment among adults with chronic Chagas disease
living in Santa Fe City (Argentina), over a mean follow-up of 21 years:
Parasitological, serological and clinical evolution. Rev Soc Bras
Med Trop . 2007;40(1):1-10. doi:10.1590/s0037-86822007000100001
115. Parrado R, Ramirez JC, de la Barra A, et al. Usefulness of serial
blood sampling and PCR replicates for treatment monitoring of patients
with chronic Chagas disease. Antimicrob Agents Chemother .
2019;63(2):e01191-18. doi:10.1128/AAC.01191-18
116. Alonso-Padilla J, Gallego M, Schijman AG, Gascon J. Molecular
diagnostics for Chagas disease: up to date and novel methodologies.Expert Rev Mol Diagn . 2017;17(7):699-710.
doi:10.1080/14737159.2017.1338566
117. Gonzalez NL, Moroni S, Moscatelli G, et al. Early antiparasitic
treatment prevents progression of Chagas disease: Results of a long-term
cardiological follow-up study in a pediatric population. medRxiv .
July 2020:2020.06.30.20143370. doi:10.1101/2020.06.30.20143370
118. Viotti R, Vigliano C, Álvarez MG, et al. Impact of aetiological
treatment on conventional and multiplex serology in chronic chagas
disease. Costa Santiago H da, ed. PLoS Negl Trop Dis .
2011;5(9):e1314. doi:10.1371/journal.pntd.0001314
119. Fabbro D, Velazquez E, Bizai ML, et al. Avaliação do tratamento
tripanossomicida em coorte de adultos chagásicos crônicos através de
técnicas sorológicas convencionais e ELISA-F29. Rev Inst Med Trop
Sao Paulo . 2013;55(3):167-172. doi:10.1590/S0036-46652013000300005
120. Altcheh J, Corral R, Biancardi MA FH. Anti-F2/3 antibodies as cure
marker in children with congenital Trypanosoma cruzi infection.Med (B Aires) . 2003;63(1):37-40.
121. Pinho RT, Waghabi MC, Cardillo F, Mengel J, Antas PRZ. Scrutinizing
the biomarkers for the neglected chagas disease: How remarkable!Front Immunol . 2016;7(AUG). doi:10.3389/fimmu.2016.00306
122. Requena-Méndez A, López MC, Angheben A, et al. Evaluating Chagas
disease progression and cure through blood-derived biomarkers: a
systematic review. Expert Rev Anti Infect Ther .
2013;11(9):957-976. doi:10.1586/14787210.2013.824718
123. Russomando G, De Tomassone MMC, De Guillen I, et al. Treatment of
congenital Chagas disease diagnosed and followed up by the Polymerase
Chain Reaction. Am J Trop Med Hyg . 1998;59(3):487-491.
doi:10.4269/ajtmh.1998.59.487
124. Bianchi F, Cucunubá Z, Guhl F, et al. Follow-up of an Asymptomatic
Chagas Disease Population of Children after Treatment with Nifurtimox
(Lampit) in a Sylvatic Endemic Transmission Area of Colombia. 2015;9(2).
doi:10.1371/ journal.pntd.0003465
125. Sguassero Y, Cuesta CB, Roberts KN, et al. Course of chronic
Trypanosoma cruzi infection after treatment based on parasitological and
serological tests: A systematic review of follow-up studies. PLoS
One . 2015;10(10):1-23. doi:10.1371/journal.pone.0139363
126. Freilij, H., Altcheh J. Chagas Disease, A Clinical Approach .
(Birkhäuser, ed.).; 2019.
127. Implementation Strategy of Bio-Molecular Techniques for Early
Diagnose of Congenital Syphilis and Chagas Diseases .
https://clinicaltrials.gov/ct2/show/NCT04084379.
128. Galvão L, Chiari E, Macedo AM, Luquetti A, Silva S, Andrade AL. PCR
Assay for Monitoring Trypanosoma cruzi Parasitemia in Childhood after
Specific Chemotherapy. J Clin Microbiol . 2003;41(11):5066-5070.
doi:10.1128/JCM.41.11.5066-5070.2003
129. Brito TK, Silva Viana RL, Gonçalves Moreno CJ, et al. Synthesis of
Silver Nanoparticle Employing Corn Cob Xylan as a Reducing Agent with
Anti-Trypanosoma cruzi Activity. Int J Nanomedicine .
2020;15:965-979. doi:10.2147/IJN.S216386
130. Arrúa EC, Seremeta KP, Bedogni GR, Okulik NB, Salomon CJ.
Nanocarriers for effective delivery of benznidazole and nifurtimox in
the treatment of chagas disease: A review. Acta Trop .
2019;198(April):105080. doi:10.1016/j.actatropica.2019.105080
131. Scarim CB, Jornada DH, Chelucci RC, de Almeida L, dos Santos JL,
Chung MC. Current advances in drug discovery for Chagas disease.Eur J Med Chem . 2018;155:824-838.
doi:10.1016/j.ejmech.2018.06.040
132. Watson JA, Strub-Wourgraft N, Tarral A, Ribeiro I, Tarning J, White
NJ. Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone
marrow toxicities of the new trypanoside fexinidazole. Antimicrob
Agents Chemother . 2019;63(4). doi:10.1128/AAC.02515-18
133. Bahia MT, Nascimento AFS, Mazzeti AL, et al. Antitrypanosomal
activity of fexinidazole metabolites, potential new drug candidates for
Chagas disease. Antimicrob Agents Chemother .
2014;58(8):4362-4370. doi:10.1128/AAC.02754-13
134. Simões-Silva MR, De Araújo JS, Peres RB, et al. Repurposing
strategies for Chagas disease therapy: The effect of imatinib and
derivatives against Trypanosoma cruzi. Parasitology .
2019;146(8):1006-1012. doi:10.1017/S0031182019000234
135. Alberca LN, Sbaraglini ML, Balcazar D, et al. Discovery of novel
polyamine analogs with anti-protozoal activity by computer guided drug
repositioning. J Comput Aided Mol Des . 2016;30(4):305-321.
doi:10.1007/s10822-016-9903-6
136. Mazzeti AL, Diniz L de F, Gonçalves KR, et al. Synergic effect of
allopurinol in combination with nitroheterocyclic compounds against
trypanosoma cruzi. Antimicrob Agents Chemother . 2019;63(6).
doi:10.1128/AAC.02264-18
137. Perez-Mazliah DE, Alvarez MG, Cooley G, et al. Sequential combined
treatment with allopurinol and benznidazole in the chronic phase of
Trypanosoma cruzi infection: a pilot study. J Antimicrob
Chemother . 2013;68(2):424-437. doi:10.1093/jac/dks390
138. Rassi A, Luquetti AO, Rassi A, et al. Specific treatment for
Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic
phase of Chagas disease. Am J Trop Med Hyg . 2007;76(1):58-61.
http://www.ncbi.nlm.nih.gov/pubmed/17255230.
139. Molina I, Gómez i Prat J, Salvador F, et al. Randomized Trial of
Posaconazole and Benznidazole for Chronic Chagas’ Disease. N Engl
J Med . 2014;370(20):1899-1908. doi:10.1056/NEJMoa1313122
140. Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic
indeterminate Chagas disease with benznidazole and three E1224 dosing
regimens: a proof-of-concept, randomised, placebo-controlled trial.Lancet Infect Dis . 2018;18(4):419-430.
doi:10.1016/S1473-3099(17)30538-8
141. Brener Z, Cançado JR, Galvão LM, et al. An experimental and
clinical assay with ketoconazole in the treatment of Chagas disease.Mem Inst Oswaldo Cruz . 88(1):149-153.
doi:10.1590/s0074-02761993000100023
142. Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and
Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers:
The STOP-CHAGAS Trial. J Am Coll Cardiol . 2017;69(8):939-947.
doi:10.1016/j.jacc.2016.12.023
143. Villalta F, Rachakonda G. Advances in preclinical approaches to
Chagas disease drug discovery. Expert Opin Drug Discov .
2019;14(11):1161-1174. doi:10.1080/17460441.2019.1652593
144. Souza HFS, Rocha SC, Damasceno FS, et al. The effect of memantine,
an antagonist of the NMDA glutamate receptor, in in vitro and in vivo
infections by Trypanosoma cruzi. PLoS Negl Trop Dis . 2019;13(9).
doi:10.1371/journal.pntd.0007226
145. Mesu VKBK, Kalonji WM, Bardonneau C, et al. Oral fexinidazole for
late-stage African Trypanosoma brucei gambiense trypanosomiasis: a
pivotal multicentre, randomised, non-inferiority trial. Lancet .
2018;391(10116):144-154. doi:10.1016/S0140-6736(17)32758-7
146. Deeks ED. Fexinidazole: First Global Approval. Drugs .
2019;79(2):215-220. doi:10.1007/s40265-019-1051-6
147. Veas R, Rojas-Pirela M, Castillo C, et al. Microalgae extracts:
Potential anti-Trypanosoma cruzi agents? Biomed Pharmacother .
2020;127. doi:10.1016/j.biopha.2020.110178
148. Albuquerque KF, Torres MDT, Lima DB, et al. Wasp venom peptide as a
new antichagasic agent. Toxicon . 2020;181:71-78.
doi:10.1016/j.toxicon.2020.04.099
149. Soares FGN, Goëthel G, Kagami LP, et al. Novel coumarins active
against Trypanosoma cruzi and toxicity assessment using the animal model
Caenorhabditis elegans. BMC Pharmacol Toxicol . 2019;20.
doi:10.1186/s40360-019-0357-z
150. Sosa A, Salamanca Capusiri E, Amaya S, et al. Trypanocidal activity
of South American Vernonieae (Asteraceae) extracts and its sesquiterpene
lactones. Nat Prod Res . 2020. doi:10.1080/14786419.2020.1739682
151. Hernández M, Wicz S, Santamaría MH, Corral RS. Curcumin exerts
anti-inflammatory and vasoprotective effects through amelioration of
NFAT-dependent endothelin-1 production in mice with acute Chagas
cardiomyopathy. Mem Inst Oswaldo Cruz . 2018;113(9):e180171.
doi:10.1590/0074-02760180171
152. Vilar-Pereira G, Carneiro VC, Mata-Santos H, et al. Resveratrol
Reverses Functional Chagas Heart Disease in Mice. Vieira LQ, ed.PLOS Pathog . 2016;12(10):e1005947.
doi:10.1371/journal.ppat.1005947
153. Robello C, Maldonado DP, Hevia A, et al. The fecal, oral, and skin
microbiota of children with Chagas disease treated with benznidazole.PLoS One . 2019;14(2):1-11. doi:10.1371/journal.pone.0212593
154. Monje Rumi M, Pérez Brandán C, Gil JF, et al. Benznidazole
treatment in chronic children infected with Trypanosoma cruzi:
Serological and molecular follow-up of patients and identification of
Discrete Typing Units. Acta Trop . 2013;128(1):130-136.
doi:10.1016/j.actatropica.2013.07.003
155. Chippaux, JP et al. Evaluation of Compliance to Congenital Chagas
Disease Treatment: Results of a Randomised Trial in Bolivia. Trans
R Soc Trop Med Hyg . 2013;107(1). doi:10.1093/TRSTMH/TRS004
156. Escribà JM, Ponce E, Romero A de D, et al. Treatment and
seroconversion in a cohort of children suffering from recent chronic
Chagas infection in Yoro, Honduras. Mem Inst Oswaldo Cruz .
2009;104(7):986-991. doi:10.1590/S0074-02762009000700008
157. Flores-Chavez M, Bosseno MF, Bastrenta B, et al. Polymerase chain
reaction detection and serologic follow-up after treatment with
benznidazole in Bolivian children infected with a natural mixture of
Trypanosoma cruzi I and II. Am J Trop Med Hyg .
2006;75(3):497-501. doi:10.4269/ajtmh.2006.75.497
158. Galvão LMC, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade
ALSS. PCR Assay for Monitoring Trypanosoma cruzi Parasitemia in
Childhood after Specific Chemotherapy. J Clin Microbiol .
2003;41(11):5066-5070. doi:10.1128/JCM.41.11.5066-5070.2003
159. Schenone F H, Contreras L M, Solari I A, García C A, Rojas S A,
Lorca H M. Nifurtimox treatment of chronic Chagasic infection in
children (2). Rev Med Chil . 2003;131(9):1089-1090.
160. Solari A. Treatment of Trypanosoma cruzi-infected children with
nifurtimox: a 3 year follow-up by PCR. J Antimicrob Chemother .
2001;48(4):515-519. doi:10.1093/jac/48.4.515
161. Solari A, Contreras MC, Lorca M, Garcia A, Salinas P, Ortiz S, Soto
A, Arancibia C SH. Yield of Xenodiagnosis and PCR in the Evaluation of
Specific Chemotherapy of Chagas’ Disease in Children. Bol Chil
Parasitol . 1998;53(1-2).
162. De Apparecida Levy AM, Boainain E KJ. In Situ Indirect Fluorescent
Antibody: A New Specific Test to Detect Ongoing Chagasic Infections.J Clin Lab Anal . 1996;10(2).
doi:10.1002/(sici)1098-2825(1996)10:2<98::aid-jcla7>3.0.co;2-h
163. Almeida IC, Covas DT, Soussumi LMT, Travassos LR. A highly
sensitive and specific chemiluminescent enzyme-linked immunosorbent
assay for diagnosis of active Trypanosoma cruzi infection.Transfusion . 1997;37(8):850-857.
doi:10.1046/j.1537-2995.1997.37897424410.x
164. Pinazo M-J, Thomas M-C, Bustamante J, Correia De Almeida I, Lopez
M-C, Gascon J. Biomarkers of therapeutic responses in chronic Chagas
disease: state of the art and future perspectives. Mem Inst
Oswaldo Cruz, Rio Janeiro . 2015;110(3):422-432.
doi:10.1590/0074-02760140435
165. Negrette OS, Valdéz FJS, Lacunza CD, et al. Serological evaluation
of specific-antibody levels in patients treated for chronic chagas’
disease. Clin Vaccine Immunol . 2008;15(2):297-302.
doi:10.1128/CVI.00106-07
166. Fabbro DL, Olivera V, Bizai ML, et al. Humoral immune response
against P2β from Trypanosoma cruzi in persons with chronic chagas
disease: Its relationship with treatment against parasites and
myocardial damage. Am J Trop Med Hyg . 2011;84(4):575-580.
doi:10.4269/ajtmh.2011.10-0261
167. Fernández-Villegas A, Pinazo MJ, Marañón C, et al. Short-term
follow-up of chagasic patients after benznidazole treatment using
multiple serological markers. BMC Infect Dis . 2011;11.
doi:10.1186/1471-2334-11-206
168. Flechas ID, Cuellar A, Cucunubá ZM, et al. Characterising the
KMP-11 and HSP-70 recombinant antigens’ humoral immune response profile
in chagasic patients. BMC Infect Dis . 2009;9(1):186.
doi:10.1186/1471-2334-9-186
169. Krautz GM, Galvão LM, Cançado JR, Guevara-Espinoza A, Ouaissi A,
Krettli AU. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein
to monitor cure of human Chagas’ disease. J Clin Microbiol .
1995;33(8):2086.
170. Krettli AU. The utility of anti-trypomastigote lytic antibodies for
determining cure of Trypanosoma cruzi infections in treated patients: An
overview and perspectives. Mem Inst Oswaldo Cruz . 2009;104(SUPPL.
1):142-151. doi:10.1590/S0074-02762009000900020
171. Cooley G, Etheridgel RD, Boehlke C, et al. High throughput
selection of effective serodiagnostics for Trypanosoma cruzi infection.PLoS Negl Trop Dis . 2008;2(10). doi:10.1371/journal.pntd.0000316
172. Meira WSF, Galvão LMC, Gontijo ED, Machado-Coelho GLL, Norris KA,
Chiari E. Use of the Trypanosoma cruzi Recombinant Complement Regulatory
Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic
Chagasic Patients. J Clin Microbiol . 2004;42(2):707-712.
doi:10.1128/JCM.42.2.707-712.2004
173. Zrein M, Granjon E, Gueyffier L, et al. A novel antibody surrogate
biomarker to monitor parasite persistence in Trypanosoma cruzi-infected
patients. PLoS Negl Trop Dis . 2018;12(2).
doi:10.1371/journal.pntd.0006226
174. Ndao M, Spithill TW, Caffrey R, et al. Identification of novel
diagnostic serum biomarkers for chagas’ disease in asymptomatic subjects
by mass spectrometric profiling. J Clin Microbiol .
2010;48(4):1139-1149. doi:10.1128/JCM.02207-09
175. Santamaria C, Chatelain E, Jackson Y, et al. Serum biomarkers
predictive of cure in Chagas disease patients after nifurtimox
treatment. BMC Infect Dis . 2014;14(1):1-12.
doi:10.1186/1471-2334-14-302
176. Pinazo M et al. Hypercoagulability biomarkers in Trypanosoma
cruzi-infected patients. Thromb Haemost . 2011;106(6):17-23.
177. Pinazo M-J, Posada E de J, Izquierdo L, et al. Altered
Hypercoagulability Factors in Patients with Chronic Chagas Disease:
Potential Biomarkers of Therapeutic Response. Correa-Oliveira R, ed.PLoS Negl Trop Dis . 2016;10(1):e0004269.
doi:10.1371/journal.pntd.0004269
178. Laucella S, Segura EL, Riarte A, Sosa ES. Soluble platelet selectin
(sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1)
decrease during therapy with benznidazole in children with indeterminate
form of Chagas’ disease. Clin Exp Immunol . 1999;118(3):423-427.
doi:10.1046/j.1365-2249.1999.01070.x
179. Dutra WO, Da Luz ZMP, Cançado JR, et al. Influence of parasite
presence on the immunologic profile of peripheral blood mononuclear
cells from chagasic patients after specific drug therapy. Parasite
Immunol . 1996;18(11):579-585. doi:10.1046/j.1365-3024.1996.d01-29.x
180. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, et al.
Benznidazole treatment during early-indeterminate Chagas’ disease
shifted the cytokine expression by innate and adaptive immunity cells
toward a type 1-modulated immune profile. Scand J Immunol .
2006;64(5):554-563. doi:10.1111/j.1365-3083.2006.01843.x
181. Argüello RJ, Albareda MC, Alvarez MG, et al. Inhibitory receptors
are expressed by Trypanosoma cruzi-specific effector T cells and in
hearts of subjects with chronic chagas disease. PLoS One .
2012;7(5). doi:10.1371/journal.pone.0035966